DLX6-AS1: A Potential Drug Target Or Biomarker (G285987)

Target Name: DLX6-AS1

NCBI ID: G285987

DLX6-AS1

Other Name(s): Evf-2 | DLX6-AS | DLX6AS | DLX6 antisense RNA 1 | NCRNA00212

DLX6-AS1: A Potential Drug Target Or Biomarker

DLX6-AS1 (Evf-2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the evolutionary family of cytoskeletal proteins, known as the axonobutyron, and is involved in the regulation of cell shape and movement.

DLX6-AS1 has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its activity.

The protein encoded by the DLX6-AS1 gene is composed of 215 amino acid residues and has a calculated molecular weight of 24.5 kDa. It consists of a cytoplasmic tail, a N-terminus, and an C-terminus that is located within the central actinin complex of the axonobutyron. The N-terminus of DLX6-AS1 is located at the base of the first nucleotide, and the C-terminus is located at the base of the second nucleotide.

DLX6-AS1 is a protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. It is a member of the evolutionary family of cytoskeletal proteins, known as the axonobutyron, and is involved in the regulation of cell shape and movement.

The cytoplasmic tail of DLX6-AS1 is the longest portion of the protein and is responsible for its ability to move and change shape in response to various stimuli, such as changes in the concentration of available nutrients or the application of mechanical forces. The N-terminus of DLX6-AS1 is located at the base of the first nucleotide, and the C-terminus is located at the base of the second nucleotide.

DLX6-AS1 has been shown to play a role in the regulation of cell shape and movement. It is involved in the formation of the actinin complex, which is a complex of the cytoskeleton and the actinin protein that is involved in the regulation of cell shape and movement. The actinin complex helps to maintain the integrity of the cytoskeleton and is involved in the regulation of various cellular processes, including cell division, migration, and mechanical forces.

DLX6-AS1 has also been shown to be involved in the regulation of cell adhesion. It is part of the adhesion complex, which is responsible for the formation of tight junctions, which are specialized barriers that help to maintain the integrity of tissues and are involved in the regulation of various cellular processes, including cell signaling and interactions.

In addition to its role in cell shape and movement and cell adhesion, DLX6-AS1 has also been shown to play a role in the regulation of cell signaling. It is involved in the regulation of various signaling pathways, including the regulation of cell proliferation, differentiation, and survival. It is also involved in the regulation of cellular signaling pathways that are involved in the regulation of inflammation and immune responses.

The potential drug target or biomarker properties of DLX6-AS1 make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its activity. Its unique structure and subcellular localization make it an ideal target for small molecules that can interact with it at the protein level, such as inhibitors of tyrosination or inhibitors of the activity of the cytoskeleton and the actinin protein. Similarly, antibodies that recognize and bind to

Protein Name: DLX6 Antisense RNA 1

The "DLX6-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLX6-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets